The aflatoxin-induced TP53 mutation at codon 249 (R249S): biomarker of exposure, early detection and target for therapy
- PMID: 19376640
- DOI: 10.1016/j.canlet.2009.02.057
The aflatoxin-induced TP53 mutation at codon 249 (R249S): biomarker of exposure, early detection and target for therapy
Abstract
Hepatocellular Carcinoma (HCC) in high-incidence areas (sub-Saharan Africa, South-Eastern Asia) often contains a somatic mutation at codon 249 in TP53 (R249S). This mutation is rare in low-incidence areas of Europe and the United States. There is evidence that R249S occurs as the result of mutagenesis by aflatoxin in a context of HBV chronic infection. Here, we summarize the mechanisms of R249S formation and the possible role of p.R249S protein in HCC pathogenesis. Next, we discuss the significance of R249S as a biomarker to study the natural history of HCC and as a target for therapeutic approaches aimed at restoring wild-type p53 activity.
Similar articles
-
TP53 R249S mutations, exposure to aflatoxin, and occurrence of hepatocellular carcinoma in a cohort of chronic hepatitis B virus carriers from Qidong, China.Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1638-43. doi: 10.1158/1055-9965.EPI-08-1102. Epub 2009 Apr 14. Cancer Epidemiol Biomarkers Prev. 2009. PMID: 19366907
-
Effects of the TP53 p.R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein.Carcinogenesis. 2010 Aug;31(8):1475-82. doi: 10.1093/carcin/bgq118. Epub 2010 Jun 10. Carcinogenesis. 2010. PMID: 20538734
-
Hepatitis B, aflatoxin B(1), and p53 codon 249 mutation in hepatocellular carcinomas from Guangxi, People's Republic of China, and a meta-analysis of existing studies.Cancer Epidemiol Biomarkers Prev. 2001 Jun;10(6):617-25. Cancer Epidemiol Biomarkers Prev. 2001. PMID: 11401911
-
TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer.Oncogene. 2007 Apr 2;26(15):2166-76. doi: 10.1038/sj.onc.1210279. Oncogene. 2007. PMID: 17401425 Review.
-
TP53 and hepatocellular carcinoma.Pathol Biol (Paris). 1997 Dec;45(10):864-70. Pathol Biol (Paris). 1997. PMID: 9769950 Review.
Cited by
-
A global view of hepatocellular carcinoma: trends, risk, prevention and management.Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):589-604. doi: 10.1038/s41575-019-0186-y. Epub 2019 Aug 22. Nat Rev Gastroenterol Hepatol. 2019. PMID: 31439937 Free PMC article. Review.
-
Status of primary liver cancer found through routine health check-up.J Korean Med Sci. 2013 Oct;28(10):1449-53. doi: 10.3346/jkms.2013.28.10.1449. Epub 2013 Sep 25. J Korean Med Sci. 2013. PMID: 24133348 Free PMC article.
-
TP53 Mutations and HBX Status Analysis in Hepatocellular Carcinomas from Iran: Evidence for Lack of Association between HBV Genotype D and TP53 R249S Mutations.Hepat Res Treat. 2011;2011:475965. doi: 10.1155/2011/475965. Epub 2011 Aug 17. Hepat Res Treat. 2011. PMID: 21869931 Free PMC article.
-
Droplet digital PCR detects high rate of TP53 R249S mutants in cell-free DNA of middle African patients with hepatocellular carcinoma.Clin Exp Med. 2018 Aug;18(3):421-431. doi: 10.1007/s10238-018-0502-9. Epub 2018 May 10. Clin Exp Med. 2018. PMID: 29749584
-
Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols.World J Hepatol. 2015 Sep 18;7(20):2274-91. doi: 10.4254/wjh.v7.i20.2274. World J Hepatol. 2015. PMID: 26380652 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous